Literature DB >> 8769464

Comparison of soft tissue Ewing's sarcoma and peripheral neuroectodermal tumor.

K A Siebenrock1, A G Nascimento, M G Rock.   

Abstract

Thirty-four cases with either extraskeletal Ewing's sarcoma (21 patients) or malignant peripheral neuroectodermal tumor of the soft tissues (13 patients) were reviewed retrospectively. The patients were treated between 1964 and 1991. Followup periods averaged 7.2 years for patients with peripheral neuroectodermal tumors and 10.4 years for patients with Ewing's sarcoma (minimal followup of 2 years). There were no significant differences in patient's age, gender, tumor location, and stages on presentation between patients with Ewing's sarcoma and those with malignant peripheral neuroectodermal tumor of the soft tissue. All but 2 patients underwent surgery for tumor resection. Adjunctive therapy (radiation or chemotherapy or both) was administered in 95% of the patients with Ewing's sarcoma and in 85% of the patients with peripheral neuroectodermal tumors. The 5-year overall survival was 50% for Ewing's sarcoma and 44% for peripheral neuroectodermal tumor. The 5-year disease free survival was 33% for both types of tumors. Survival rates were higher for Stage III compared with Stage IV disease for both types of tumors. There was a tendency for better outcome after complete surgical tumor resection. Survivors tended to be of a younger age at the time of tumor diagnosis. The results suggest that from a clinical perspective, these 2 tumors are quite similar.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769464     DOI: 10.1097/00003086-199608000-00036

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  6 in total

1.  Primary peripheral primitive neuroectodermal tumors of the spinal cord: report of two cases and review of the literature.

Authors:  R Perry; I Gonzales; J Finlay; S Zacharoulis
Journal:  J Neurooncol       Date:  2007-01-03       Impact factor: 4.130

2.  Prognostic factors and clinical outcome of patients with Ewing's sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology.

Authors:  Erkan Arpaci; Tarkan Yetisyigit; Metin Seker; Dogan Uncu; Ummugul Uyeturk; Berna Oksuzoglu; Umut Demirci; Ugur Coskun; Mehmet Kucukoner; Abdurrahman Isıkdogan; Mevlude Inanc; Necati Alkis; Metin Ozkan
Journal:  Med Oncol       Date:  2013-01-24       Impact factor: 3.064

3.  Extraskeletal Ewing sarcoma in children and adolescents: impact of narrow but negative surgical margin.

Authors:  Sajid S Qureshi; Siddharth Laskar; Seema Kembhavi; Sanjay Talole; Girish Chinnaswamy; Tushar Vora; Mukta Ramadwar; Saral Desai; Nehal Khanna; Mary Ann Muckaden; Purna Kurkure
Journal:  Pediatr Surg Int       Date:  2013-08-28       Impact factor: 1.827

4.  Histopathologic and Radiologic Assessment of Chemotherapeutic Response in Ewing's Sarcoma: A Review.

Authors:  José M García-Castellano; Nagib Atallah Yordi; Carolina Reyes; John H Healey
Journal:  Sarcoma       Date:  2012-03-01

5.  Characterization, survival analysis, and expression of IGFR in tumor samples from patients diagnosed with Ewing family tumors treated at the Barretos Cancer Hospital.

Authors:  Adriano Jander Ferreira; Erica Boldrini; Rossana Verónica Mendoza López; Cristovam Scapulatempo Neto; Julie Francine Cerutti Santos; Luiz Fernando Lopes
Journal:  Rev Bras Ortop       Date:  2016-12-31

Review 6.  A review of soft-tissue sarcomas: translation of biological advances into treatment measures.

Authors:  Ngoc T Hoang; Luis A Acevedo; Michael J Mann; Bhairavi Tolani
Journal:  Cancer Manag Res       Date:  2018-05-10       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.